(Q38339579)

2 September 2017

0 references

1 reference

title

Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials (English)

1 reference

2 September 2017

author

José Luis Calvo-Guirado

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25639776%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

José Luis Calvo Guirado

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25639776%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Rafael A Delgado-Ruiz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25639776%20AND%20SRC:MED&resulttype=core&format=json

Antonio Aguilar-Salvatierra

1 June 2020

5

object named as

Antonio Aguilar-Salvatierra

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25639776%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

2

Gerardo Gómez-Moreno

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25639776%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Ana Boquete-Castro

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25639776%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

2 February 2015

1 reference

Clinical Oral Implants Research

2 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25639776%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25639776%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25639776%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

367-375

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25639776%20AND%20SRC:MED&resulttype=core&format=json

Osteonecrosis of the jaw in a patient on Denosumab

1 June 2020

cites work

1 reference

The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data

21 January 2018

1 reference

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

21 January 2018

1 reference

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

21 January 2018

1 reference

Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review

21 January 2018

1 reference

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.

21 January 2018

1 reference

The role and efficacy of denosumab in the treatment of osteoporosis: an update

21 January 2018

1 reference

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

21 January 2018

1 reference

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases

21 January 2018

1 reference

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

21 January 2018

1 reference

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs

21 January 2018

1 reference

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

21 January 2018

1 reference

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

21 January 2018

1 reference

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

21 January 2018

1 reference

Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice

21 January 2018

1 reference

21 January 2018

1 reference

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.

21 January 2018

1 reference

Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension

21 January 2018

1 reference

Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial.

21 January 2018

1 reference

Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates

21 January 2018

1 reference

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

21 January 2018

1 reference

Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.

21 January 2018

1 reference

Denosumab for the treatment of osteoporosis: a systematic literature review.

21 January 2018

1 reference

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

21 January 2018

1 reference

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

Osteonecrosis of the jaws induced by anti-RANK ligand therapy

21 January 2018

1 reference

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

21 January 2018

1 reference

Antiresorptive drug-related osteonecrosis of the jaw.

21 January 2018

1 reference

Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?

21 January 2018

1 reference

RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?

21 January 2018

1 reference

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

21 January 2018

1 reference

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

21 January 2018

1 reference

Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases

21 January 2018

1 reference

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

Effects of denosumab on fracture and bone mineral density by level of kidney function

21 January 2018

1 reference

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 January 2018

1 reference

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

21 January 2018

1 reference

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/CLR.12556

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25639776%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference